Patents & IP

A platform you build on — owned, not licensed in.

NeoPep’s delivery platform is proprietary. TD‑IntelGel™ and Muco‑SmartSeal® are our own patented technologies — which means partners build a differentiated peptide line on IP we control end to end, without depending on a third party’s formulation.

What’s protected

The IP behind the platform.

Two proprietary technologies work together to carry a fragile peptide across the buccal membrane and hold it in place.

Delivery platform

TD‑IntelGel™

Our trans-diffusion intelligent gel — a tri-layer hydrogel that stabilises the peptide and drives controlled diffusion through the cheek lining.

Retention seal

Muco‑SmartSeal®

An edge-sealing system that maintains prolonged mucosal contact and prevents peptide loss into saliva.

Content pending from NeoPep: exact patent status and scope (filed / granted), jurisdictions/territories covered, application or grant numbers, and priority dates. Share these and we will publish a precise, partner-ready IP position here.

Why it matters to partners

What owned IP means for your business.

1

A defensible line

You resell a format competitors can’t simply copy — the differentiation is protected, not generic.

2

One accountable source

Platform, manufacturing and finished product sit with one owner — no licensing chain to manage or renegotiate.

3

Cleaner diligence

A clear IP position is one of the first things procurement and BD teams ask for — we make it easy to review.

4

Room to co-develop

Licensing and OEM routes let pharma and biotech partners bring their own molecules onto the platform.

Reviewing NeoPep for a partnership?

We provide a partner IP summary and supporting documentation under NDA on request.